Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 1, 2015, Pages 38-45

  Pullarkat, Vinod ^a   Aldoss, Ibrahim ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Chemosensitivity; Day 14 bone marrow; Early response; Reinduction

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME DISORDER; CLINICAL PRACTICE; CYTOGENETICS; EARLY INTERVENTION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; LEUKOCYTOSIS; MEDICAL TECHNOLOGY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RETREATMENT; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SURVIVAL TIME; TREATMENT RESPONSE; BONE MARROW; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PATHOLOGY; PROCEDURES; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 84930819048     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.01.005     Document Type: Review

References (23)

1. Arellano M., Pakkala S., Langston A., et al. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer 2012, 118:5278-5282.
2. Elliott M.A., Litzow M.R., Letendre L.L., et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007, 110:4172-4174.
3. Liso V., Albano F., Pastore D., et al. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica 2000, 85:1285-1290.
4. Hussein K., Jahagirdar B., Gupta P., Burns L., Larsen K., Weisdorf D. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. Am J Hematol 2008, 83:446-450.
5. Bertoli S., Bories P., Béné M.C., et al. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. Haematologica 2014, 99:46-53.
6. Kern W., Haferlach T., Schoch C., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003, 101:64-70.
7. Yanada M., Borthakur G., Ravandi F., Bueso-Ramos C., Kantarjian H., Estey E. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 2008, 93:1263-1265.
8. Grosicki S., Holowiecki J., Giebel S., et al. The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study. Am J Hematol 2011, 86:437-439.
9. Ofran Y., Hayun M., Leiba R., et al. Early bone marrow examination, on the fifth day of induction for AML, is highly predictive of response. ASH Ann Meet Abstr 2013, 122:3893.
10. Gianfaldoni G., Mannelli F., Bencini S., Leoni F., Baldini S., Bosi A. Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. Blood 2008, 111:1746-1747.
11. Lacombe F., Arnoulet C., Maynadié M., et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009, 23:350-357.
12. Gianfaldoni G., Mannelli F., Ponziani V., Longo G., Bencini S., Bosi A., et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010, 95:833-836.
13. Hou H.A., Shih T.T., Liu C.Y., et al. Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Haematologica 2010, 95:1420-1424.
14. Shih T.T., Hou H.A., Liu C.Y., et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009, 113:3161-3167.
15. Chen B.B., Hsu C.Y., Yu C.W., et al. Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission. Radiology 2011, 258:821-831.
16. Büchner T., Urbanitz D., Hiddemann W., et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985, 3:1583-1589.
17. Wheatley K., Burnett A.K., Goldstone A.H., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107:69-79.
18. Rowe J.M., Kim H.T., Cassileth P.A., et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010, 116:5012-5021.
19. Büchner T., Hiddemann W., Wörmann B., et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999, 93:4116-4124.
20. Heil G., Krauter J., Raghavachar A., et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤60 years: results of a prospective multicenter trial. Ann Hematol 2004, 83:336-344.
21. Wakita A., Ohtake S., Takada S., et al. Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. Int J Hematol 2012, 96:84-93.
22. Othus M., Sudipto M., Sekeres M.A., et al. Prediction of CR on reinduction in patients with newly diagnosed acute myeloid leukemia given intensive induction regimens: a report from SWOG and Cleveland Clinic. ASH Ann Meet Abstr 2013, 122:3924.
23. Bertoli S., Bérard E., Huguet F., et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood 2013, 121:2618-2626.